Adaptive Biotechnologies Corporation (ADPT) Stock Forecast
ADPT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.56 / 5 from 9 analysts
- Price target
- $29.81 average of analyst targets
- Upside to target
- +24.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.10
- 52-week range
- $12.41 – $29.84
ADPT analyst ratings
9 analystsNumber of analysts at each rating.
ADPT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ADPT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.11 | −$0.08 | $0.06 | −259.2% | 7 |
| Current fiscal year (2026) | −$0.54 | −$0.57 | −$0.51 | −$0.39 | −39.1% | 7 |
| Next fiscal year (2027) | −$0.18 | −$0.32 | −$0.01 | −$0.54 | +66.8% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ADPT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $71.6M | $70.0M | $73.0M | −23.8% | 8 |
| Current fiscal year (2026) | $293.4M | $290.6M | $296.9M | +5.9% | 9 |
| Next fiscal year (2027) | $359.2M | $345.0M | $371.3M | +22.4% | 9 |
ADPT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ADPT revenue: reported and forecast
ADPT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.10 | −$0.10 | −$0.10 | −$0.10 | −14.7% | 7 up · 0 down |
| Current fiscal year (2026) | −$0.45 | −$0.54 | −$0.54 | −$0.54 | −$0.54 | +19.9% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.24 | −$0.18 | −$0.18 | −$0.18 | −$0.18 | −23.9% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ADPT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ADPT beat in 11 of 12.
What analysts expect from ADPT
9 analysts cover Adaptive Biotechnologies; their consensus rating is strong buy (4.56 on a 1–5 scale, where 5 is a strong buy). The average price target is $29.81, 24.1% above the latest close of $24.02. Analysts expect earnings of −$0.54 per share for 2026, −39.1% from a year earlier. For 2027 the average estimate is −$0.18 per share on revenue of $359.2 million. Adaptive Biotechnologies beat the EPS estimate in 11 of the last 12 quarters.
Related: ADPT income statement, ADPT key metrics, ADPT chart. See the ADPT stock overview for the latest quote and news.
ADPT forecast FAQ
What is Adaptive Biotechnologies's price target?
The average analyst price target for Adaptive Biotechnologies is $29.81, 24.1% above the latest close of $24.02.
Is Adaptive Biotechnologies a buy, hold or sell?
Of 9 analysts covering Adaptive Biotechnologies, 6 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Adaptive Biotechnologies's EPS forecast?
Analysts forecast −$0.54 per share for 2026 (range −$0.57 to −$0.51); for 2027 the estimate is −$0.18.
What is Adaptive Biotechnologies's revenue forecast?
The average revenue estimate for 2026 is $293.4 million, growth of 5.9%; for 2027 it is $359.2 million.
When does Adaptive Biotechnologies report earnings?
Adaptive Biotechnologies is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.10.
Does Adaptive Biotechnologies usually beat earnings estimates?
Adaptive Biotechnologies reported EPS at or above the analyst estimate in 11 of the last 12 quarters.